ClinicalTrials.gg
RecruitingNCT06338683Updated Mar 29, 2024

Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer

A Phase 3 interventional study of Olanzapine 2.5 MG and Standard anti-tumor treatment in Advanced Cancer, Olanzapine and Progression Free Survival, sponsored by Qinghai Red Cross Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-29.

Sponsored by Qinghai Red Cross Hospital · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
230
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study aims to assess the impact of adding olanzapine to nutritional advice and standard anti-tumor therapy on the survival and safety of patients with locally advanced, unresectable or metastatic gastric cancer, esophageal cancer, hepato-pancreaticobiliary cancer, and lung cancer. Researchers seek to determine whether olanzapine can improve progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) in advanced cancer patients who received standard anti-tumor therapy, and investigate the relationship between olanzapine-induced weight changes and patient survival.

Read the detailed description

This study is a prospective, randomized, multicenter, open-label clinical trial to evaluate the effect of olanzapine on survival in patients with locally advanced, unresectable, or metastatic gastric, esophageal, hepato-pancreaticobiliary, and lung cancer. Patients who meet the inclusion and exclusion criteria will be formally enrolled after screening and signing an informed consent form. Eligible patients will be dynamically randomized in a 1:1 ratio to either the Olanzapine + Nutritional advice + Standard anti-tumor treatment group (ONS group) or the Nutritional advice + Standard anti-tumor treatment group (NS group). The ONS group will receive olanzapine treatment orally until disease progression. Survival outcomes, including median PFS, OS, and ORR, will be monitored during treatment through follow-up assessments.

In addition, baseline and post-treatment weight data will be collected to assess the incidence of weight loss and changes in body mass index (BMI) among patients. Researchers will collect survey questionnaires and conduct blood analyses to evaluate improvements in other symptoms associated with olanzapine and changes in quality of life and inflammatory markers. Primary and secondary study outcomes and adverse events will be assessed.

02

Conditions studied

  • Advanced Cancer
  • Olanzapine
  • Progression Free Survival

Keywords

  • advanced cancer
  • olanzapine
  • chemotherapy
  • progression free survival
03

In context

Lead sponsor

Qinghai Red Cross Hospital is the lead sponsor of 6 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 years or older;
  2. performance status of 0-3;
  3. Stage III or IV inoperable or gastric cancer, esophageal cancer, hepato-pancreaticobiliary cancer and lung cancer confirmed by histology or cytology;
  4. Subjected to palliative systemic chemotherapy, regardless of or second-line treatment;
  5. Expected survival ≥ 3 months;
  6. The patient is eligible for oral administration without dietary restrictions;
  7. Exhibits a favorable adherence to treatment and follow-up, demonstrates compliance with the research protocol, and willingly signs the form.

Exclusion criteria

Exclusion Criteria:

  1. Weight loss and gain may be attributed to alternative factors, such as edema or ascites;
  2. Suffers from mental disorders or is under the medication of any antipsychotic or antidepressant drugs;
  3. History of central nervous system disorders (such as , epilepsy;
  4. Patients undergoing sustained administration of sedative medications or long-term hormonal therapy, individuals with chronic alcoholism, or those with substance dependence on medications;
  5. Prohibition of Olanzapine Intake for Individuals;
  6. History of clozapine-induced agranulocytosis because patients will be at increased risk for neutropenia with Olanzapine;
  7. Uncontrolled diabetes mellitus and Uncontrolled seizure disorder;
  8. Pregnant and Nursing women;
  9. Exclusion criteria include active participation in another interventional clinical trial, ongoing involvement in an observational (noninterventional) clinical trial, or being in the survival follow-up phase of an interventional clinical trial;
  10. Researchers posit that any condition deemed potentially harmful to the subjects or that might prevent subjects from meeting or adhering to the research requirements shall not be permissible for inclusion in this study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
230 participants (estimated)

Study arms

  • Experimental
    Arm I (ONS group)

    Patients receive olanzapine 2.5mg PO until disease progression. Intervention: Patients received olanzapine and nutritional advice and standard antitumor treatment.

    Drug: Olanzapine 2.5 MG · Drug: Standard anti-tumor treatment · Dietary Supplement: Nutritional advice

  • Placebo comparator
    Arm II (NS group)

    No Intervention: Patients received nutritional advice and standard anti-tumor treatment.

    Drug: Standard anti-tumor treatment · Dietary Supplement: Nutritional advice

Interventions

  • DrugOlanzapineStudies of OlanzapineOlanzapine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oral olanzapine 2.5 mg once daily at bedtime until disease progression

  • DrugStandard anti-tumor treatment

    Clinicians choose the appropriate standard antitumor drug therapy based on the patient's specific situation

  • Dietary supplementNutritional advice

    All patients enrolled in the study were required to undergo a nutritional assessment and were provided with nutritional advice based on their condition

06

What researchers measure

Primary outcomes

  1. Comparing the difference in Median PFS between the two groups

    PFS was defined as the time between the start of treatment in this study and the onset of (any aspect of) tumor progression or death (from any cause). Assessment through the RECICT 1.1 version of solid tumors

    Time frame: 2 years

Secondary outcomes

  1. Comparing the difference in Median OS between the two groups

    OS was defined as the time from the start of randomization to death due to any cause. Assessment through the RECICT 1.1 version of solid tumors

    Time frame: 2 years

  2. Comparing the difference in ORR between the two groups

    ORR was defined as the proportion of patients with advanced disease who achieved complete or partial remission after treatment. Assessment through the RECICT 1.1 version of solid tumors

    Time frame: 2 years

  3. Comparing the difference in the incidence of ≥3% weight loss between the two groups

    Patients will receive weight measurements every 2 cycles. Over a 2-year period, the incidence of ≥3% weight loss until progression between the two groups will be assessed based on patients' baseline and post-treatment measurements to determine the efficacy of the drug.

    Time frame: 2 years

  4. Comparing the difference in BMI between the two groups

    The BMI will be calculated by dividing weight in Kg with the square of the body height (in m2), and is expressed in units of kg/m2. Weight will be recorded by a high quality calibrated digital scale. Participants would be instructed to keep light cloths according to their comfort and no foot-ware. Weight will be expressed in kilograms (Kg) and same machine will be used during each recoding, preferably during the same hour of the day. Height will be measured using a stadiometer, in centimeters (cm) using the metric system. Comparison of BMI (BMI \<20 kg/m2; BMI 20-25 kg/m2; BMI \>25 kg/m2) between the two groups

    Time frame: 2 years

  5. Comparing the difference in the improvement in other symptoms (appetite, nausea, fatigue, insomnia) between the two groups

    Patients will be asked to fill the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) Anorexia/Cachexia Subscale (A/CS) questionnaire (investigator assisted) for the other symptoms both validated with a set cut-off values before start of chemotherapy treatment and after every 2 weeks. These instruments will be presented to the patients on paper and assistance will be offered if required. Both instruments will be filled out based on the patient's experience regarding their appetite during the last 7 days. The 12 items of the FAACT-A/CS are scored on a five-point Likert scale (0 = not at all, 1 = a little bit, 2 = somewhat, 3 = quite a bit, and 4 = very much). The scores of negatively worded items should be reversed. The sum score ranges from 0 to 48, whereby a lower score indicates less appetite. For scoring the FAACT-A/CS, the FACIT manual will be applied. The cut-off values of ≤37 on the FAACT-A/CS had the highest predictive values.

    Time frame: 2 years

  6. Comparing the difference in Quality of life in the overall stage between the two groups

    Assessment through the EuroQol Five Dimensions Questionnaire (EQ-5D). EQ-5D is a standardized instrument used for assessing an individual's health-related quality of life. It comprises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has three levels that describe the person's level of functioning or well-being in that specific area. Additionally, EQ-5D includes a visual analog scale where individuals rate their overall health on a scale from 0 (worst imaginable health) to 100 (best imaginable health)

    Time frame: 2 years

  7. neutrophil-to-lymphocyte ratio

    Comparing the difference in Changes in inflammatory factor neutrophil-to-lymphocyte ratio

    Time frame: 2 years

  8. platelet-to-lymphocyte ratio

    Comparing the difference in Changes in inflammatory factor

    Time frame: 2 years

  9. C-reactive protein (CRP) concentration

    Comparing the difference in Changes in inflammatory factor

    Time frame: 2 years

  10. concentration of albumin

    Comparing the difference in Changes in inflammatory factor

    Time frame: 2 years

  11. Level of interleukin (IL)-6 and IL-8

    Comparing the difference in Changes in inflammatory factor , through the examination of blood profiles

    Time frame: 2 years

  12. Comparing the difference in the side effects of olanzapine treatment between the two groups

    The proportion of side effects related to olanzapine treatment in patients evaluated by Common Terminology Criteria for adverse events Version 5.0

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2024 (actual). Primary completion is estimated for Mar 2027, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2024
First posted
Mar 29, 2024
StartActual
Mar 20, 2024
Primary completionEst.
Mar 20, 2027
CompletionEst.
Mar 20, 2028
Last update
Mar 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06338683
Lead sponsor
Qinghai Red Cross Hospital
Responsible party
Sponsor
First posted
Mar 29, 2024
Start date
Mar 20, 2024
Primary completion
Mar 20, 2027 (estimated)
Completion
Mar 20, 2028 (estimated)
Last update
Mar 29, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olanzapine

Start the discussion